Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Centanafadine 400 mg	49
Overall Study	STARTED	Centanafadine 200 mg	49
Overall Study	STARTED	Placebo	49
Overall Study	Safety Analysis Set	Centanafadine 400 mg	49
Overall Study	Safety Analysis Set	Centanafadine 200 mg	49
Overall Study	Safety Analysis Set	Placebo	49
Overall Study	Efficacy Analysis Set	Centanafadine 400 mg	49
Overall Study	Efficacy Analysis Set	Centanafadine 200 mg	48
Overall Study	Efficacy Analysis Set	Placebo	47
Overall Study	COMPLETED	Centanafadine 400 mg	36
Overall Study	COMPLETED	Centanafadine 200 mg	39
Overall Study	COMPLETED	Placebo	40
Overall Study	NOT COMPLETED	Centanafadine 400 mg	13
Overall Study	NOT COMPLETED	Centanafadine 200 mg	10
Overall Study	NOT COMPLETED	Placebo	9

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05113953/flow